Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 57.58 USD 0.44% Market Closed
Market Cap: 116.8B USD
Have any thoughts about
Bristol-Myers Squibb Co?
Write Note

Wall Street
Price Targets

BMY Price Targets Summary
Bristol-Myers Squibb Co

Wall Street analysts forecast BMY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BMY is 60.56 USD with a low forecast of 33.43 USD and a high forecast of 76.65 USD.

Lowest
Price Target
33.43 USD
42% Downside
Average
Price Target
60.56 USD
5% Upside
Highest
Price Target
76.65 USD
33% Upside

BMY Last Price Targets
Bristol-Myers Squibb Co

The latest public price target was made on Nov 12, 2024 by Evan Seigerman from BMO Capital , who expects BMY stock to rise by 6% over the next 12 months. You can read more about this price target by viewing the article on TheFly.

Analyst Price Target Date Article
Evan Seigerman
BMO Capital
61 USD
Upside 6%
1 month ago
Nov 12, 2024
Bristol Myers price target raised to $61 from $57 at BMO Capital
TheFly
Evan David Seigerman
BMO Capital
57 USD
Downside 1%
1 month ago
Nov 1, 2024
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at BMO Capital
StreetInsider
Evan David Seigerman
BMO Capital
48 USD
Downside 17%
3 months ago
Sep 23, 2024
BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
StreetInsider
Carter Gould
Barclays
41 USD
Downside 29%
4 months ago
Jul 29, 2024
Bristol Myers downgraded to Underweight from Equal Weight at Barclays
TheFly
Chris Shibutani
Goldman Sachs
57 USD
Downside 1%
4 months ago
Jul 29, 2024
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at Goldman Sachs
StreetInsider
Trung Huynh
UBS
43 USD
Downside 25%
5 months ago
Jul 12, 2024
Bristol Myers price target lowered to $43 from $47 at UBS
TheFly
Steve Scala
Cowen & Co.
67 USD
Upside 16%
7 months ago
May 16, 2024
TD Cowen Reiterates Hold Rating on Bristol-Myers Squibb Co. (BMY)
StreetInsider
James Shin
Deutsche Bank
55 USD
Downside 4%
10 months ago
Jan 30, 2024
Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts?
Benzinga
Evan Seigerman
BMO Capital
60 USD
Upside 4%
1 year ago
Nov 27, 2023
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Benzinga
David Risinger
Leerink Partners
66 USD
Upside 15%
1 year ago
Oct 12, 2023
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Benzinga
Louise Chen
Cantor Fitzgerald
75 USD
Upside 30%
1 year ago
Sep 6, 2023
How To Earn $500 From Pfizer Stock With Shares Trading At 52-Week Low
Benzinga
Show More Price Targets
Show Less Price Targets
Evan Seigerman
BMO Capital
Price Target 61 USD
Upside/Downside 6%
View Source
Evan David Seigerman
BMO Capital
Price Target 57 USD
Upside/Downside 1%
View Source
Evan David Seigerman
BMO Capital
Price Target 48 USD
Upside/Downside 17%
View Source
Carter Gould
Barclays
Price Target 41 USD
Upside/Downside 29%
View Source
Chris Shibutani
Goldman Sachs
Price Target 57 USD
Upside/Downside 1%
View Source
Trung Huynh
UBS
Price Target 43 USD
Upside/Downside 25%
View Source
Steve Scala
Cowen & Co.
Price Target 67 USD
Upside/Downside 16%
View Source
James Shin
Deutsche Bank
Price Target 55 USD
Upside/Downside 4%
View Source
Evan Seigerman
BMO Capital
Price Target 60 USD
Upside/Downside 4%
View Source
David Risinger
Leerink Partners
Price Target 66 USD
Upside/Downside 15%
View Source
Louise Chen
Cantor Fitzgerald
Price Target 75 USD
Upside/Downside 30%
View Source
Show More Price Targets
Show Less Price Targets
Bristol-Myers Squibb Co Competitors:
Price Targets
SUNPHARMA
Sun Pharmaceutical Industries Ltd
13% Upside
IPN
Ipsen SA
20% Upside
002332
Zhejiang Xianju Pharmaceutical Co Ltd
61% Upside

Revenue
Forecast

Revenue Estimate
Bristol-Myers Squibb Co

For the last 8 years the compound annual growth rate for Bristol-Myers Squibb Co's revenue is 13%. The projected CAGR for the next 4 years is 0%.

13%
Past Growth
0%
Estimated Growth
Estimates Accuracy
0%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Bristol-Myers Squibb Co

For the last 8 years the compound annual growth rate for Bristol-Myers Squibb Co's operating income is 23%. The projected CAGR for the next 4 years is 11%.

23%
Past Growth
11%
Estimated Growth
Estimates Accuracy
-37%
Average Miss

Net Income
Forecast

Net Income Estimate
Bristol-Myers Squibb Co

For the last 8 years the compound annual growth rate for Bristol-Myers Squibb Co's net income is 23%. The projected CAGR for the next 4 years is 14%.

23%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-57%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BMY's stock price target?
Price Target
60.56 USD

According to Wall Street analysts, the average 1-year price target for BMY is 60.56 USD with a low forecast of 33.43 USD and a high forecast of 76.65 USD.

What is Bristol-Myers Squibb Co's Revenue forecast?
Projected CAGR
0%

For the last 8 years the compound annual growth rate for Bristol-Myers Squibb Co's revenue is 13%. The projected CAGR for the next 4 years is 0%.

What is Bristol-Myers Squibb Co's Operating Income forecast?
Projected CAGR
11%

For the last 8 years the compound annual growth rate for Bristol-Myers Squibb Co's operating income is 23%. The projected CAGR for the next 4 years is 11%.

What is Bristol-Myers Squibb Co's Net Income forecast?
Projected CAGR
14%

For the last 8 years the compound annual growth rate for Bristol-Myers Squibb Co's net income is 23%. The projected CAGR for the next 4 years is 14%.

Back to Top